Abstract Categories
- 1a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)
- 1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)
- 1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)
- 1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)
- 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (all aspects)
- 1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)
- 1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)
- 1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV)
- 1i. Other
- 2a. Tuberculosis and other mycobacterial infections (incl antimycobacterial drugs, treatment & susceptibility/resistance, diagnostics & epidemiology)
- 2b. Severe sepsis, bacteraemia & endocarditis (incl host bio-markers)
- 2c. Community-acquired respiratory infections
- 2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections
- 2e. Skin, soft tissue, bone & joint (excl prostheses) & central nervous system infections
- 2f. Zoonotic bacterial diseases (incl foodborne and waterborne pathogens and One Health aspects)
- 2g. Other intracellular or rare bacteria
- 2h. Other
- 3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives
- 3b. Resistance surveillance & epidemiology: Gram-negatives
- 3c. Susceptibility testing methods (incl assay validation and comparative studies, excl TB)
- 3d. Resistance mechanisms (excl TB)
- 3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)
- 3f. Clinical outcome of resistant infections (excl trials of new drugs)
- 3g. Spread of resistance incl reservoirs, ecology, mobile elements (excl nosocomial transmission)
- 3h. Other
- 4a. Diagnostic bacteriology – culture based and general microbiology
- 4b. Lab management, automation and QC
- 4c. MALDI-TOF and other proteomic methods
- 4d. Molecular diagnostics (incl POCT and syndromic testing)
- 4e. Strain typing and surveillance (methods other than genomics)
- 4f. Whole genome sequencing (diagnostic, typing)
- 4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)
- 4h. Clinical metagenomics
- 4i. Bioinformatics tools & pipelines
- 4j. Other
- 5a. Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents
- 5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring
- 5c. New or repurposed antibacterial agents: clinical trials
- 5d. Pharmacoepidemiology (incl economics and cost-effectiveness), improved prescribing and antibiotic stewardship (incl decision-support / prediction tools, behavioural aspects)
- 5e. Safety and adverse effects of treatment
- 5f. Other
- 6a. Fungal disease epidemiology
- 6b. Diagnostic mycology (incl molecular)
- 6c. Antifungal drugs & treatment (incl clinical trials)
- 6d. Antifungal resistance & susceptibility testing (incl surveillance)
- 6e. Other
- 7a. Diagnostic parasitology
- 7b. Antiparasitic susceptibility & resistance
- 7c. Antiparasitic drugs & treatment
- 7d. Parasitic disease epidemiology
- 7e. Travel medicine & migrant health
- 7f. Food & water safety and environmental health
- 7g. International & public health
- 7h. Other
- 8a. Intravascular catheter-related infections
- 8b. Other foreign-body and implant infections
- 8c. Surgical site infections
- 8d. Healthcare-associated pneumonia
- 8e. Hospital epidemiology, transmission, surveillance & screening (incl. environment)
- 8f. Other healthcare associated infections (incl CDI)
- 8g. Infection control interventions and trials (incl. microbiota transplantation)
- 8h. Disinfection & biocides
- 8i. Other
- 9a. Microbial pathogenesis & virulence
- 9b. Host-pathogen interaction (including basic microbiome studies)
- 9c. Preclinical biofilm studies
- 9d. Experimental and cellular microbiology
- 9e. Other
- 10a. Host genetics: infection susceptibility & immunodeficiency
- 10b. Clinical epidemiology and treatment of infections in immunocompromised hosts
- 10c. General vaccinology (incl. policy, social aspects)
- 10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses)
- 10e. Antibacterial vaccines
- 10f. Immune response to infection (excl sepsis biomarkers)
- 10g. Other
- 11a. Education and career
- 11b. Publishing, ethics, other academic and professional affairs
- 11c. Other
- 12a. Basic science and virology
- 12b. Epidemiology- local, regional, global
- 12c. Clinical features, case management, outcome
- 12d. Diagnostics
- 12e. Drug development and treatment modalities (incl. clinical trials)
- 12f. Immune response, immunomodulation
- 12g. Vaccine development and trials
- 12h. Infection control
- 12i. Public health policy, mitigation
- 12j. Preparedness and response
- 12k. Other societal aspects (incl. economics)
- 12l. Other
- 21. New drugs
- 22. Clinical trials
- 23. COVID-19
- 24. Outbreaks and public health emergencies other than COVID-19